Home

  • 3rd analysis of BCIRG 006 presented by Dr Slamon on December 12 at the 2009 SABCS conference (GENERAL SESSION 5 -Exhibit Hall D)
    Abstract 62. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC -> T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC -> TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study

  • Click here to access the official BCIRG 006 Presentation in pdf format (Slides set in jpg format - zipped file)

  • 2nd analysis of CIRG/TORI 010 study presented at the 2009 SABCS conference by Dr John Mackey from the Cross cancer Institute , abstract 47 CIRG/TORI 010: First Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel (P) as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC)

    Click here to access the official CIRG/TORI 010 Presentation

  • Analysis of Fcg Receptor IIa and IIIa Polymorphisms: Correlation with Outcome in Trastuzumab-Treated Her2/neu Amplified Early and Metastatic Breast Cancer Patients (from breast cancer patients treated in the BCIRG-006 study) presented by Dr. Sara Hurvitz from UCLA at 2009 SABCS conference. Abstract 64 Click here to access slides presentation

  • For information on new TRIO-CIRG studies please click in the Studies Summary on left side menu.

________________________________________________________

  • CIRG Paris office has moved to a new location, please note our new address:

    CIRG - Biopark - 11, rue Watt 75013 Paris France

________________________________________________________

The Art of Oncology - A decade's contribution and experience of the BCIRG in changing the breast cancer paradigm
_____________________________________

Following the merge of CIRG and TORI late 2005, they are now officially incorporated in a new structure named:

TRIO
Translational Research In Oncology
 
CIRG and TORI are respectively keeping their activities and names and as such, are divisions of the new group TRIO.
 
The aim of this new group is to further the objective of bringing rational and innovative therapeutic concepts into the clinical trial setting.
  • Translate preclinical findings into clinical research
  • Use translational  approaches based on the underlying biology of the disease
  • Conduct innovative clinical research across all phases of drug development and multiple disease sites 

For more details on this new structure please access  to the newly website: http://www.trioncology.org

_____________________________________

TORI  (founded by Dr Dennis Slamon) is an oncology research network linked to several basic research laboratories which evaluate new therapeutic molecules.
TORI labs uses molecularly characterized models of various human malignancies to study new agents to guide the design of Phase I and Phase II Clinical Studies. 
Once leading compounds are ready for larger studies, CIRG and its proven network of committed investigators can perform these larger translational trials.

____________________________________________________________

For  information on the CIRG clinical studies recent outcome, click on  Studies in the left menu